Close this search box.

Roivios® and its’ wholly owned R&D subsidiary, 3ive Labs, LLC, are clinical-stage medical device companies striving to sustain or enhance kidney function during time of acute stress

We’re initially focused on providing a first-to-market solution to sustain or enhance kidney function for patients with impaired kidney function during a cardiac surgery with cardiopulmonary bypass.

Renal Insufficiency Meets Stress

Patients with renal insufficiency undergoing cardiac surgery are at significant risk for developing peri-operative complications.1-5
Surgeon in operating room

Poor Outcomes for Patients With Renal Impairment

When the kidneys fail, the patient fails.

Acute kidney injury (AKI) in patients with CKD has significant impact on patients and care systems.

increase in cost of care5-8
2 x
extended hospital stay risk9
5 x
operative mortality rate9,10
7 x
increase in dialysis risk*9
55 x

*Compared to patients with normal eGFR, patients with CKD 4 (<30) have 55x the incidence of dialysis (10.9% vs 0.2%).

Supercharging the kidneys

At Roivios, we believe enhancing the natural intra-renal pressures with mild, targeted negative pressure will enable optimal kidney function and improve patient outcomes.

And, we’re on a mission to prove it.

Abstract representing supercharging a kidney

The JuxtaFlow® Renal Assist Device (RAD)

Roivios is developing a first-of-its-kind treatment designed to sustain or enhance kidney function in patients undergoing cardiac surgery with pre-existing renal insufficiency.

Learn about BIPASS-AKI

Find info about our clinical study

Meet our Team

See what makes us different

Contact Us

Connect with our team


  1. Bowdish ME, D’Agostino RS, Thourani VH, et al. STS Adult Cardiac Surgery Database: 2021 Update on Outcomes, Quality, and Research. Ann Thorac Surg. 2021;111(6):1770-1780.
  2. Robert AM, Kramer RS, Dacey LJ, et al. Cardiac surgery-associated acute kidney injury: a comparison of two consensus criteria. Ann Thorac Surg. 2010;90(6):1939-1943.
  3. Palomba H, de Castro I, Neto AL, Lage S, Yu L. Acute kidney injury prediction following elective cardiac surgery: AKICS Score. Kidney Int. 2007;72(5):624-631.
  4. Brown JR, Kramer RS, Coca SG, Parikh CR. Duration of acute kidney injury impacts long-term survival after cardiac surgery. Ann Thorac Surg. 2010;90(4):1142-1148.
  5. Shen W, Aguilar R, Montero AR, et al. Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study. Am J Nephrol. 2017;45(3):217-225.
  6. LaPar DJ, Rich JB, Isbell JM, et al. Preoperative Renal Function Predicts Hospital Costs and Length of Stay in Coronary Artery Bypass Grafting. Ann Thorac Surg. 2016;101(2):606-612.
  7. HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD.
  8. Hobson C, Ozrazgat-Baslanti T, Kuxhausen A, et al. Cost and Mortality Associated With Postoperative Acute Kidney Injury. Ann Surg. 2015;261(6):1207-1214.
  9. Cooper WA, O’Brien SM, Thourani VH, et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation. 2006;113(8):1063-1070.
  10. Griffin BR, Bronsert M, Reece TB, et al. Creatinine elevations from baseline at the time of cardiac surgery are associated with postoperative complications. J Thorac Cardiovasc Surg. 2022;163(4):1378-1387.